$VCYT

Febbo Phillip G. sold $564K of VCYT

Febbo Phillip G. (Chief Scientific & Med Officer) sold 13,110 shares of VERACYTE, INC. (VCYT) at an average of $43.05 ($42.89–$43.66, $0.56M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Febbo Phillip G.
Published Sep 4, 2026, 11:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 11:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VCYT
Bearish
medium confidence
Mentioned
$VCYT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VCYTBearishLow
01

Why it matters

The disclosed sale is the first public report of this insider's transaction, offering fresh data for traders.

02

Market read

A mid-sized insider sale provides a modest signal; limited impact unless accompanied by other news.

03

What to watch

Potential upcoming corporate events or financing needs not disclosed could be driving the sale.

Relevance 4/10Novelty 3/10Timing: same-day

Background

Form 4 filing discloses insider transactions; investors monitor such sales for signals.

Company-level read

Ticker impact

$VCYTBearishMedium confidence
Context

Chief Scientific & Med Officer Phillip G. Febbo sold 13,110 shares for $564K via a 10b5-1 plan on Sep 4, 2026.

Expected impact

Modest downward pressure; price may dip 1-2% if market reacts.

Evidence & confidence

Sale size is modest relative to market cap, but insider status adds weight; no other catalyst present.

Counterpoint

The sale could be a routine liquidity move, not a negative signal; price may remain stable.

Key entities

  • Veracyte, Inc.

    Medical diagnostics company listed on NASDAQ under VCYT.

  • Phillip G. Febbo

    Chief Scientific & Med Officer at Veracyte.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VCYTHigh

VERACYTE, INC. (VCYT): Results of Operations and Financial Condition

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veracyte Announces Second Quarter 2026 Financial Results Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCIS